Recent data on a large cohort of DLBCL treated uniformly with rituximab-CHOP also confirmed the negative prognostic relevance of the MYC+/BCL2+ phenotype, with concomitant TP53 mutation conferring an even worse prognosis in such cases [63]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.